Navigation Links
Amgen to Collaborate With GlaxoSmithKline to Commercialize Denosumab in Europe for Postmenopausal Osteoporosis (PMO)
Date:7/27/2009

together are uniquely positioned to help medical providers and patients understand the clinical promise and economic value of denosumab."

"This pioneering treatment that Amgen has developed will be a strong addition to our biopharmaceuticals portfolio," commented Andrew Witty, CEO of GlaxoSmithKline. "The data for denosumab is very encouraging and we believe it will provide significant benefit and value to patients with postmenopausal osteoporosis and other bone disease conditions. Together with Amgen we are committed to increasing worldwide access to this medicine."

In July 2007, Amgen granted Daiichi Sankyo exclusive rights to develop and commercialize denosumab in Japan in PMO and oncology with the potential for additional indications. This arrangement remains in place.

About Denosumab

Denosumab is a fully human monoclonal antibody that targets RANK Ligand and is being investigated for its potential to prevent and treat a broad range of bone disease conditions including osteoporosis, bone metastases and their consequences, cancer treatment-induced bone loss due to hormone ablative therapy, multiple myeloma and bone erosions in rheumatoid arthritis. Denosumab is the first late-stage investigational therapy that specifically inhibits RANK Ligand, an essential mediator of the cells that break down bone. With more than 19,000 patients in trials across indications worldwide, the denosumab development program is the largest ever initiated by Amgen. This broad and deep development program demonstrates Amgen's commitment to researching and delivering pioneering medicines to patients with unmet medical needs.

Amgen has submitted marketing applications for denosumab in the United States, European Union, Canada, Switzerland, and Australia.

About Osteoporosis

Often referred to as the "silent epidemic," osteoporosis is a global problem that is
'/>"/>

SOURCE Amgen; GlaxoSmithKline
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Amgen and Genentech Brace Themselves for Heavy Pressure From Biogenerics Manufacturers
2. More Than 230 Cyclists to Ride in Amgen California Coast Classic Bike Tour to Raise $1.3 Million for Arthritis Foundation
3. Entry of Biogenerics and Decreasing Use of Amgens Epogen and Johnson & Johnsons Procrit Will Cause a $2.8 Billion Decline in the Drug Market for Chemotherapy-Induced Anemia by 2016
4. Oxford Genome Sciences and Amgen to Jointly Discover Novel Therapeutic Antibodies in Cancer
5. Pfizer, Genentech, Amgen, Bayer, Wyeth, Abbott, Merck and Additional Leading Pharmaceutical Companies Participating During ExL Pharmas Fall Line Up!
6. Co-Inventor of Amgens Aranesp(R) Technology Directs Worldwide Patent Strategy for Diffusion Pharmaceuticals First-in-Class Oxygen Enhancing Therapeutics
7. Amgen Announces Webcast of 2008 Third Quarter Financial Results
8. Amgens Third Quarter 2008 Adjusted Earnings Per Share Increased 14 Percent to $1.23
9. Call for Applications: The Amgen Award for Science Teaching Excellence
10. Amgen to Webcast 2008 Business Review Meeting on November 7 From Millennium Hotel in New York
11. Amgen Positioned to Deliver Attractive Growth Over Next Five Years
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... Dallas, TX, USA (PRWEB) , ... July 30, ... ... nano and microsystems, has appointed Francois Vieillard as Sales & Marketing Director. ... executive positions, Francois Vieillard will be responsible for reinforcing Tronics’ business development activities ...
(Date:7/30/2015)... VANCOUVER, Washington , July 30, 2015 ... "Biosimulation Market, by Product (Software, Molecular Modeling, PB/PK, PKPD, ... (Drug Discovery & Development, Preclinical, Clinical Trial), by End ... the Biosimulation Market is expected to reach USD 2,107.99 ... at a CAGR of 15.29%. Browse ...
(Date:7/30/2015)... 2015   Aratana Therapeutics, Inc . (NASDAQ: ... on the licensing, development and commercialization of innovative ... its strategic partner VetStem Biopharma, Inc. has shared ... AT-016, an adipose-derived allogeneic stem cell product exclusively ... pain in dogs. The double-blinded, multi-site, ...
(Date:7/30/2015)... 60,000 customers across the globe, ISN improves the efficiency and effectiveness of contractor management ... safe and reliable contractors in over 80 countries. ... ... Over 60,000 Worldwide Customers In More Than 80 ... Headquartered in Dallas, TX , ISN has additional offices in ...
Breaking Biology Technology:Tronics appoints Francois Vieillard as Sales and Marketing Director 2Biosimulation Market Worth 2,107.99 Million USD by 2020 2Biosimulation Market Worth 2,107.99 Million USD by 2020 3Biosimulation Market Worth 2,107.99 Million USD by 2020 4Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 2Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 3Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 4Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 5ISN Reaches Over 60,000 Worldwide Customers 2ISN Reaches Over 60,000 Worldwide Customers 3
... Inc., (NYSE: CRY ),a biomaterials, medical device ... first CryoValve(R) SG pulmonary human heart,valve since the ... Administration,(FDA) in February. The procedure was performed on ... Louis, Mo. The CryoValve SG is processed with,the ...
... RepHresh,Vaginal Gel(R) is now available to women in Canada., ... to educate women about their,feminine health, RepHresh Vaginal Gel ... comes to discussing a highly volatile and often,embarrassing subject, ... a successful dialogue between women,doctors, and the media that ...
... for clean water stretches even the resources of the world,s ... technology and novel ideas to find solutions. , Mark Shannon ... of world leaders in water resource research to address this ... issue of Nature. , "As dire as the growing problems ...
Cached Biology Technology:CryoLife Announces Implant of First FDA-Cleared SynerGraft(R) Processed Human Pulmonary Heart Valve 2CryoLife Announces Implant of First FDA-Cleared SynerGraft(R) Processed Human Pulmonary Heart Valve 3pH Balanced RepHresh Vaginal Gel(R) now Available to Women in Canada Attacking Tough, Embarrassing Feminine Issues 2pH Balanced RepHresh Vaginal Gel(R) now Available to Women in Canada Attacking Tough, Embarrassing Feminine Issues 3Countering an approaching water crisis 2
(Date:7/13/2015)... Calif. , July 13, 2015 ... developer of human interface solutions, today announced sampling ... touch and display driver integration (TDDI) product targeting ... the first to combine Synaptics , best-in-class ... proven display driver technology developed in the company,s ...
(Date:7/9/2015)... , July 9, 2015  Synaptics ... developer of human interface solutions, today announced ... industry,s first fully hardware encapsulated fingerprint sensor ... authentication technology is literally off the grid, ... biometric matching within the fingerprint sensor to ...
(Date:7/7/2015)... , June 30, 2015 ... has announced the addition of the "Capacitive ... offering. To this date, fingerprint sensing ... technology and fingerprint sensors are well developed. This ... sensing technology. The domain of capacitive ...
Breaking Biology News(10 mins):Synaptics Announces Sampling of Second Generation TDDI Solutions 2Synaptics Announces Sampling of Second Generation TDDI Solutions 3Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 2Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 3Worldwide Capacitive Fingerprint Sensors Patent Landscape Market Report 2015-2020 - Main IP Holders include Seiko Epson, AuthenTec, Sony and STMicroelectronics 2
... battle between the bacterial pathogen Salmonella and the ... at the Biozentrum of the University of Basel has now ... host,s immune system. Their findings are published in the scientific ... is a bacterial infection caused by the pathogen Salmonella ...
... atom located in the vicinity of a molecule can change ... international team of researchers was able to change persistently positions ... by approaching a single copper atom to the molecule. ... simple organic molecule can be switched by approaching a single ...
... or the pipes of an organ, the proteins in the ... Now, a new study provides what researchers say is ... a technique they developed based on terahertz near-field microscopy, scientists ... (HWI) have for the first time observed in detail the ...
Cached Biology News:Typhoid fever -- A race against time 22-proton bit controlled by a single copper atom 22-proton bit controlled by a single copper atom 3The symphony of life, revealed 2The symphony of life, revealed 3
Ideally suited for resolving DNA and RNA 10-1000 bases especially PCR products ranging from 100-1000 bp. Gelling temp. (4%) 27C Melting temperature 65C. EEO: 0.10 Rnase/Dnase: none detected...
XEDAR Antibody...
Xanthine Oxidase (Bovine Buttermilk). Monospecific by IEP. Some cross reactivity with Xanthine Oxidase of other species and tissues may occur....
Rabbit Anti-JNK1/SAPK pan, Polyclonal Antibody...
Biology Products: